See more : Creades AB (0QI9.L) Income Statement Analysis – Financial Results
Complete financial analysis of Precipio, Inc. (PRPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precipio, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Nisshinbo Holdings Inc. (3105.T) Income Statement Analysis – Financial Results
- X1 Entertainment Group Inc. (XONE.CN) Income Statement Analysis – Financial Results
- Goodfellow Inc. (GDL.TO) Income Statement Analysis – Financial Results
- Changshu Fengfan Power Equipment Co., Ltd. (601700.SS) Income Statement Analysis – Financial Results
- Xebec Adsorption Inc. (XBC.TO) Income Statement Analysis – Financial Results
Precipio, Inc. (PRPO)
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.20M | 9.41M | 8.85M | 6.09M | 3.13M | 2.86M | 1.72M | 1.56M | 1.65M | 27.08M | 27.54M | 31.48M | 31.97M | 20.05M | 22.02M | 23.99M | 23.18M | 23.42M | 25.83M | 33.79M | 33.87M | 37.55M | 38.47M | 25.88M | 23.03M |
| Cost of Revenue | 9.18M | 6.90M | 6.46M | 4.94M | 2.91M | 2.64M | 1.43M | 1.76M | 1.94M | 17.36M | 15.05M | 16.47M | 13.53M | 10.28M | 10.42M | 10.35M | 10.48M | 12.05M | 13.50M | 24.60M | 24.32M | 19.57M | 17.20M | 10.89M | 10.58M |
| Gross Profit | 6.02M | 2.51M | 2.39M | 1.15M | 219.00K | 225.00K | 292.00K | -205.00K | -287.00K | 9.72M | 12.50M | 15.01M | 18.44M | 9.76M | 11.61M | 13.65M | 12.69M | 11.37M | 12.33M | 9.19M | 9.55M | 17.99M | 21.27M | 14.99M | 12.46M |
| Gross Profit Ratio | 39.60% | 26.67% | 27.03% | 18.88% | 7.00% | 7.86% | 16.95% | -13.17% | -17.36% | 35.89% | 45.37% | 47.68% | 57.67% | 48.70% | 52.69% | 56.88% | 54.77% | 48.55% | 47.74% | 27.21% | 28.20% | 47.89% | 55.29% | 57.92% | 54.09% |
| Research & Development | 0.00 | 1.70M | 1.30M | 1.20M | 1.20M | 1.10M | 500.00K | 1.42M | 1.85M | 2.90M | 3.21M | 2.49M | 2.22M | 2.31M | 3.18M | 2.47M | 3.03M | 2.36M | 2.20M | 6.69M | 9.31M | 12.20M | 9.37M | 7.65M | 6.30M |
| General & Administrative | 10.32M | 13.51M | 10.61M | 9.00M | 8.32M | 9.45M | 6.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 8.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.42M | 13.61M | 10.71M | 9.10M | 8.42M | 9.45M | 6.49M | 6.19M | 7.06M | 24.15M | 25.04M | 22.02M | 19.15M | 10.93M | 10.32M | 10.80M | 11.47M | 12.14M | 12.22M | 17.50M | 17.32M | 24.20M | 21.64M | 14.91M | 11.53M |
| Other Expenses | 3.22M | 15.31M | 12.01M | 10.30M | 9.62M | -1.33M | 877.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 425.00K | 10.50M | 4.77M | 0.00 | 0.00 | 1.91M | 1.51M |
| Operating Expenses | 13.64M | 15.31M | 12.01M | 10.30M | 9.62M | 9.45M | 6.49M | 7.61M | 8.91M | 27.04M | 28.26M | 24.51M | 21.37M | 13.24M | 13.50M | 13.26M | 14.50M | 14.50M | 14.84M | 34.68M | 31.40M | 36.40M | 31.01M | 24.47M | 19.34M |
| Cost & Expenses | 22.82M | 22.21M | 18.46M | 15.24M | 12.53M | 12.09M | 7.92M | 9.38M | 10.85M | 44.41M | 43.30M | 40.98M | 34.90M | 23.52M | 23.92M | 23.61M | 24.98M | 26.55M | 28.34M | 59.28M | 55.72M | 55.97M | 48.21M | 35.36M | 29.92M |
| Interest Income | 0.00 | 12.00K | 20.00K | 470.00K | 2.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 74.00K | 270.00K | 216.00K | 0.00 | 0.00 | 160.00K | 626.00K | 2.45M | 2.01M | 0.00 |
| Interest Expense | 18.00K | 12.00K | 20.00K | 470.00K | 473.00K | 0.00 | 2.32M | 0.00 | 0.00 | 665.00K | 642.00K | 888.00K | 958.00K | 4.00K | 15.00K | 74.00K | 0.00 | 11.00K | 1.98M | 2.38M | 315.00K | 62.00K | 58.00K | 1.78M | 0.00 |
| Depreciation & Amortization | 1.52M | 1.52M | 1.44M | 1.36M | 1.35M | 1.27M | 743.00K | 112.00K | 489.00K | 2.25M | 2.75M | 2.28M | 2.10M | 708.00K | 855.00K | 882.00K | 950.00K | 1.95M | 4.28M | 4.01M | 8.75M | 3.99M | 3.68M | 1.91M | 1.51M |
| EBITDA | -4.32M | -10.65M | -7.05M | -8.77M | -8.22M | -7.96M | -5.45M | -1.60M | -8.65M | -10.51M | -12.65M | -5.02M | -830.00K | -2.27M | -1.04M | 600.00K | -981.00K | -973.00K | 1.77M | -6.76M | -7.44M | -18.28M | -6.06M | -7.57M | -5.37M |
| EBITDA Ratio | -28.41% | -119.82% | -92.32% | -109.24% | -205.50% | -111.66% | 353.86% | -523.12% | -513.43% | -80.83% | -58.52% | -22.95% | 15.70% | -16.26% | -8.62% | 8.39% | -1.99% | -5.02% | 10.32% | -12.99% | -21.96% | -29.33% | -15.67% | -32.22% | -23.31% |
| Operating Income | -7.62M | -12.80M | -9.61M | -9.15M | -9.40M | -13.91M | -15.51M | -7.82M | -9.20M | -17.32M | -15.76M | -9.50M | -2.97M | -3.61M | -1.90M | -368.00K | -3.32M | -3.13M | -2.51M | -29.06M | -22.59M | -21.70M | -9.74M | -9.48M | -6.88M |
| Operating Income Ratio | -50.14% | -135.96% | -108.63% | -150.13% | -300.74% | -485.75% | -900.23% | -502.18% | -556.26% | -63.96% | -57.21% | -30.19% | -9.30% | -18.02% | -8.61% | -1.53% | -14.33% | -13.37% | -9.72% | -86.00% | -66.70% | -57.78% | -25.32% | -36.61% | -29.88% |
| Total Other Income/Expenses | 1.77M | 619.00K | 1.10M | -1.45M | -2.32M | -2.06M | -5.18M | -515.00K | -1.22M | 3.90M | -282.00K | 1.32M | -6.77M | 628.00K | 18.00K | 86.00K | 243.00K | 198.00K | -2.45M | -5.26M | -5.82M | -2.98M | 2.36M | 996.00K | -1.20M |
| Income Before Tax | -5.85M | -12.18M | -8.52M | -10.60M | -13.31M | -15.97M | -20.69M | -8.27M | -10.14M | -13.42M | -16.04M | -8.18M | -9.74M | -2.98M | -1.88M | -282.00K | -1.93M | -2.93M | -4.96M | -34.47M | -22.89M | -21.26M | -7.38M | -8.48M | -8.08M |
| Income Before Tax Ratio | -38.51% | -129.39% | -96.25% | -173.97% | -425.74% | -557.72% | -1,201.04% | -531.09% | -613.31% | -49.54% | -58.24% | -25.99% | -30.46% | -14.88% | -8.53% | -1.18% | -8.33% | -12.53% | -19.20% | -102.00% | -67.60% | -56.61% | -19.18% | -32.77% | -35.08% |
| Income Tax Expense | 0.00 | 25.00K | 33.00K | 1.63M | -70.00K | -279.00K | 13.87M | -203.00K | 23.76M | 524.00K | -54.00K | 146.00K | 45.00K | 150.00K | 42.00K | 213.00K | 243.00K | 30.00K | 26.00K | -94.00K | 65.00K | 105.00K | 24.00K | 180.00K | 1.75M |
| Net Income | -5.85M | -12.20M | -8.55M | -12.23M | -13.24M | -15.69M | -20.69M | -7.62M | -32.95M | -13.94M | -15.99M | -8.33M | -9.78M | -3.13M | -1.92M | -495.00K | -2.11M | -3.43M | -14.99M | -34.37M | -22.96M | -21.37M | -7.40M | -8.66M | -9.83M |
| Net Income Ratio | -38.51% | -129.65% | -96.62% | -200.76% | -423.50% | -547.97% | -1,201.04% | -489.15% | -1,993.59% | -51.48% | -58.04% | -26.45% | -30.60% | -15.63% | -8.72% | -2.06% | -9.09% | -14.65% | -58.05% | -101.73% | -67.79% | -56.89% | -19.24% | -33.46% | -42.66% |
| EPS | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.81 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| EPS Diluted | -4.51 | -10.73 | -8.10 | -14.84 | -46.51 | -217.80 | -1.34K | -158.45K | -24.07K | -837.26 | -990.09 | -646.66 | -1.07K | -343.68 | -210.78 | -54.34 | -231.31 | -376.70 | -2.27K | -6.40K | -5.06K | -4.89K | -1.77K | -2.81K | -4.08K |
| Weighted Avg Shares Out | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
| Weighted Avg Shares Out (Dil) | 1.30M | 1.14M | 1.05M | 823.85K | 284.76K | 72.06K | 15.46K | 48.06 | 1.37K | 16.65K | 16.15K | 12.88K | 9.14K | 9.12K | 9.11K | 9.11K | 9.11K | 9.11K | 6.61K | 5.37K | 4.53K | 4.37K | 4.18K | 3.08K | 2.41K |
Two Smaller Companies Worthy of Your "Attention"
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2024 Earnings Conference Call November 18, 2024 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Good day. Welcome to the Precipio Third Quarter 2024 Shareholder Update Conference Call.
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients
Precipio Announces Employee Stock Option Plan Repricing
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their effectiveness as a retention tool for valuable...
Zacks Initiates Coverage of Precipio With Outperform Recommendation
Discover why Zacks rates Precipio as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore PRPO's approaching breakeven milestones, financial health, and market positioning in the cancer diagnostics space.
Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2024 Earnings Conference Call August 19, 2024 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Second Quarter 2024 Shareholder Update Conference Call. All participants will be in...
Precipio Announces Q2-2024 Shareholder Update Call
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET.
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
Company's continued growth and improved cash position alleviates the need for capital raise in the foreseeable future Company's continued growth and improved cash position alleviates the need for capital raise in the foreseeable future
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
Pathology Revenues in June exceed breakeven target and continue growth trend Pathology Revenues in June exceed breakeven target and continue growth trend
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time
Source: https://incomestatements.info
Category: Stock Reports